

**DESCRIPTION**


<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human Fibulin 5/DANCE in direct ELISAs and Western blots.
<b>Source</b>	Monoclonal Mouse IgG <sub>1</sub> Clone # 293904
<b>Purification</b>	Protein A or G purified from hybridoma culture supernatant
<b>Immunogen</b>	Mouse myeloma cell line NS0-derived recombinant human Fibulin 5/DANCE Gln24-Phe448 Accession # Q9UBX5
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 µm filtered solution in PBS.

**APPLICATIONS**

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	<b>Recommended Concentration</b>	<b>Sample</b>
<b>Western Blot</b>	1 µg/mL	See Below
<b>Immunohistochemistry</b>	8-25 µg/mL	Immersion fixed paraffin-embedded sections of human lung

**DATA**



**PREPARATION AND STORAGE**

<b>Reconstitution</b>	Reconstitute at 0.5 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>• 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>• 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>• 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

**BACKGROUND**

Fibulin 5, also known as DANCE and EVEC, is a secreted 55 kDa matricellular glycoprotein that plays an important role in elastic fiber network assembly and angiogenesis (1). Mature human Fibulin 5 contains an N-terminal EGF-like domain with an RGD motif, a 44 amino acid (aa) spacer region, five more tandem EGF-like domains, and a 115 aa Fibulin-like C-terminal region (2, 3). Mature human Fibulin 5 shares 95% aa sequence identity with mouse and rat Fibulin 5. Fibulin 5 is expressed by smooth muscle cells and endothelial cells of the developing vasculature as well as by migrating neural crest cells and lung interstitial fibroblasts (2-4). It is down-regulated in the adult vasculature but is re-expressed at aortic branching points, in the uterus, and at sites of mechanical or atherosclerotic injury (2, 3, 5). The RGD motif of Fibulin 5 binds to several cell surface Integrins including  $\alpha$ V $\beta$ 3,  $\alpha$ V $\beta$ 5,  $\alpha$ 9 $\beta$ 1,  $\alpha$ 4 $\beta$ 1, and  $\alpha$ 5 $\beta$ 1 (2, 6, 7). The calcium-dependent binding of Fibulin 5 to elastic fibers serves to anchor cells to the extracellular matrix (8). Fibulin 5 promotes elastic fiber assembly and maturation by organizing Tropoelastin, LTBP-2, and the crosslinking lysyl oxidase-like enzymes LOXL1, 2, and 4 along Fibrillin microfibrils (6, 9-11). In aged mice with decreased tissue elasticity, proteolytic removal of the N-terminal EGF-like domain prevents Fibulin 5 from interacting with Fibrillin-1 microfibrils (10). Fibulin 5 functions as an angiogenesis inhibitor by inhibiting vascular smooth muscle proliferation and migration and by limiting vascular sprouting (5, 12). Fibulin 5 is down-regulated in many malignancies (15). When experimentally re-expressed, however, Fibulin 5 enhances tumor cell invasiveness and cooperates with TGF- $\beta$  in initiating and promoting epithelial-mesenchymal transition (EMT) (13, 15). Defects in Fibulin 5 expression or function can result in a loss of connective tissue integrity, cardiac elasticity, and ability to remodel the vasculature after injury (8, 5, 14).

**References:**

1. Yanagisawa, H. *et al.* (2009) *J. Cell. Commun. Signal.* **3**:337.
2. Nakamura, T. *et al.* (1999) *J. Biol. Chem.* **274**:22476.
3. Kowal, R.C. *et al.* (1999) *Circ. Res.* **84**:1166.
4. Kuang, P.-P. *et al.* (2003) *Am. J. Physiol. Lung Cell. Mol. Physiol.* **285**:L1147.
5. Spencer, J.A. *et al.* (2005) *Proc. Natl. Acad. Sci.* **102**:2946.
6. Nakamura, T. *et al.* (2002) *Nature* **415**:171.
7. Lomas, A.C. *et al.* (2007) *Biochem. J.* **405**:417.
8. Yanagisawa, H. *et al.* (2002) *Nature* **415**:168.
9. Wachi, H. *et al.* (2008) *J. Biochem.* **143**:633.
10. Hirai, M. *et al.* (2007) *J. Cell Biol.* **176**:1061.
11. Hirai, M. *et al.* (2007) *EMBO J.* **26**:3283.
12. Sullivan, K.M. *et al.* (2007) *Lab. Invest.* **87**:818.
13. Lee, Y.-H. *et al.* (2008) *Carcinogenesis* **29**:2243.
14. Loeys, B. *et al.* (2002) *Hum. Mol. Genet.* **11**:2113.
15. Schiemann, W.P. *et al.* (2002) *J. Biol. Chem.* **277**:27367.